Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry

Autor: Leslie R. Harrold, Haijun Tian, Marc A Mason, Ning Guo, Abby S. Van Voorhees, Adriana Guana, Bruce Strober, Vivian Herrera

Publikováno v: Journal of Dermatological Treatment. 32:907-915

Biologic therapies have revolutionized the management of moderate-to-severe psoriasis; however, there are a limited number of US real-world studies characterizing patients based on response to these treatments. This study examined characteristics at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::029d68b91d07ca288d7229769a69ac44
https://doi.org/10.1080/09546634.2020.1720586

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study

Autor: Adriana Guana, Weibin Bao, Tsen-Fang Tsai, Yu Huei Huang, Seung-Chul Lee, Derrick Chen Wee Aw, Joo Heung Lee, Tae-Gyun Kim, Cathleen Michelle A. Dee, Min Geol Lee

Publikováno v: The Journal of Dermatology. 46:752-758

The 52-week results from the CLEAR (NCT02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient-reported outcomes, with comparable safety profile in subjects with moderate to severe ps

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90601f3462a38ee1733f048068d6a125
https://doi.org/10.1111/1346-8138.15004

Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study

Autor: Charis Papavassilis, Diamant Thaçi, Robert Bissonnette, Todd Fox, Darryl Toth, Ulrich Mrowietz, R. You, I. Messina, Isabelle Gilloteau, T. A. Luger, Adriana Guana

Publikováno v: British Journal of Dermatology. 177:1033-1042

Background Secukinumab has demonstrated significant efficacy with a good safety profile through 1 year in plaque psoriasis. Given the chronic nature of this disease, long-term follow-up is needed to evaluate psoriasis therapies fully. Objectives To d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1a0b1e64110e3190d7e7b75594e089f
https://doi.org/10.1111/bjd.15706

US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry

Autor: Heather J. Litman, Ning Guo, Adriana Guana, Jeff Greenberg, Bruce Strober, Mark Lebwohl, Rebecca Germino

Publikováno v: The Journal of dermatological treatment. 31(4)

Objective: To examine the real-world effectiveness of secukinumab with regard to clinical and patient-reported outcomes (PROs) from enrollment to a 6-month follow-up visit in patients with psoriasi...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc4637108e950e46f2016a6dbde97ef7
https://pubmed.ncbi.nlm.nih.gov/31035822

Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study

Autor: Adriana Guana, Neil J. Korman, Alice B. Gottlieb, Diamant Thaçi, Yang Zhao, Isabelle Gilloteau, Ronald Vender, Bintu Sherif, Matthias Augustin, Andrew Blauvelt, Lluís Puig, Nicole Williams, Mark Lebwohl

Publikováno v: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Background: Secukinumab has demonstrated greater sustained skin clearance than ustekinumab through week 52, greater improvement in symptoms and health-related quality of life, and comparable safety profile. Objective: To assess the impact of secukinu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464602c2227bb85e7705141f60990c31
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3808